Status:
COMPLETED
The Role of Small Intestinal Endocrine Cells in Type 2 Diabetic Hyperglucagonemia
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
35+ years
Brief Summary
The purpose of this study is to determine whether excessive secretion of glucagon in type 2 diabetes originates from the pancreatic alpha-cells or endocrine cells in the mucosa of the small intestinal...
Detailed Description
Hyperglucagonemia contributes significantly to the hyperglycemia characterizing patients with Type 2 diabetes. Fasting hyperglucagonemia induces hepatic glucose release resulting in elevated fasting l...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes for at least 3 months
- Normal hemoglobin
- Informed consent
Exclusion
- Liver disease (ALAT/ASAT \> 2 x normal range)
- Diabetic nephropathy (se-creatinin \> 130 µM and/or albuminuriu)
- Treatment with medication that can not be stopped for12 hours
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00639613
Start Date
March 1 2008
Last Update
June 26 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine F' laboratory
Hellerup, Copenhagen County, Denmark, 2900